# Danish drugmaker LEO Pharma has agreed to acquire U.S. developer Replay for $50 million.

*biotech · news · 2026-05-02 · Devdiscourse*

## Key points

- LEO Pharma is acquiring Replay for $50 million to access experimental genetic skin disease treatments.
- The FDA has proposed new restrictions on mass compounding of Novo and Lilly's weight-loss drugs.
- A second generic version of Ozempic has been approved in Canada, increasing market competition.
- Cigna will exit the U.S. Obamacare exchange market, consistent with its updated profit projections.

**Companies:** Novo Nordisk, Eli Lilly, LEO Pharma
**Countries:** Denmark, United States, Canada

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3894341-pharma-deals-surge-amid-regulatory-challenges-and-innovations)

---

Canonical: https://newsio.io/n/5de1d5fa-d978-41a4-b190-3c684bef8007/danish-drugmaker-leo-pharma-has-agreed-to-acquire-u-s-developer-replay-for-50-mi
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works